Clinical chemistry is more than reagents for performing analyses for medical purposes.
The breadth of our field is made apparent by an article in this issue by
Aarts et al. (1) concerning scheduling of tests among instruments in a laboratory.
Scheduling has always been a part of the clinical laboratory, whether in the duty roster or in the efficient work organization of that colleague we admire and envy. Work scheduling is a task that increasingly will be done by computers, and it behooves us to understand it as a technology to serve our needs rather than a technology whose need we are obliged to serve. By understanding the technology, we will be master.
Scheduling is the marshalling of resources to achieve one or more objectives. Planning is the strategic selection of the objectives, in contrast to scheduling, which is the tactical implementation of the plan. In the clinical laboratory scheduling of tests is a major application of the technology. Tests might be scheduled to achieve the lowest cost as a primary objective. This plan might entail batching the samples into a single run for instruments that must be recalibrated for each run. Another objective might be attainment of promised turnaround time. A third objective might be a reduction in the number of "in-process" specimens.
The article by Aarts et al.
(1) introduces scheduling theory applied to chemical analysis. Their objective is to complete the work in the shortest overall timewhich equates to the problem of finding the sequence of tests that allows completion in the least time. Scheduling and queue theory is a discipline unto itself, and over the past 40 years enormous effort has gone into finding efficient algorithms for producing such sequences (2). To date, the only definitive solution is to try all the possibilities. That entails sequentially trying each of n tests as the first test to be performed and making reservations for it, followed by each of the n -1 remaining tests and making reservations for those, and so on. As may be appreciated, the number of possibilities for the sequence of tests is n!, an enormous number. Even taking into account the fact that many of the sequences are equivalent because the tests for different samples are equivalent, the number of possibilities is still very large. As quickly becomes apparent, it takes longer to have the computer find the "best" sequence than to perform the tests without conscious scheduling. Even the fastest computers fail when there are a thousand tests to schedule for only one morning's run.
While the theoreticians work to find an algorithm to efficiently solve this problem, practical application will continue to rely on heuristic algorithms-i.e., rules that are not (yet) theoretically supported. Often heuristic algorithms are created by insight into the problem at hand, one way to gain insight being the study of the best of the trial sequences. Heuristics are thus valuable because they provide a way to schedule nearly optimal sequences in an acceptable period of time.
Aarts et al.
(1) show good performance from heuristic algorithms that, in combination with other criteria, first schedule the test that takes the longest time to complete. Intuitively, this makes sense: Start the long tests first, then do other tests while the first test incubates, and so on.
A key finding is the utility in designing test protocols with flexible timing, e.g., incubations that, instead of requiring exactly 30 mm, permit incubations of 30-35 mm. When such flexibility is provided, the time to completion (and the throughput) may be dramatically improved. Flexible timing is allowed when reactions are run to completion or otherwise reach a plateau. Flexible timing also may be applied to the assessment of enzyme rates. So long as the actual time of each measurement is known, the true rate can be computed. Indeed, waiting for near-completion may be in conflict with a short time to result. The superior timing capability of automated instruments permits nonequilibrium protocols; i.e., not proceeding to completion can reduce the time to result. As always, however, there are trade-offs.
Scheduling algorithms became a focus of attention in the diagnostics industry over the last decade when random-access instrument architecture (many tests multiplexed through a single high-speed general-purpose channel) replaced parallel-channel instrument architecture. Such instruments became feasible with the availability of low-cost computers to schedule the instrument resources. The first generation of scheduling algorithms mimicked the electromechanical sequencers of earlier instruments or, worse, scheduled noninterruptable batches. Subsequent generations provided features such as stat interruption, throughput optimization, error recovery, and reagent management. The challenge for the instrument designer continues to be to provide a tool that is transparent to the novice yet powerful to the sophisticate.
The work by Aarts et al. deals with a model having a single limiting resource, the pipettor. In a well-designed instrument, the limiting resource will shift with work load. This is so because hardware costs money, and it is uneconomical to invest in excess capacity. This same principle applies to overall capital costs: Why purchase throughput to complete the day's workload in 2 h if a scheduler can provide the desired throughput and turnaround with a lower-cost instrument or current instruments?
Scheduling the test is only part of the challenge. The clinical laboratory should be robust. If an instrument pipettor is plugged by a fibrin clot, how will error propagation and error recovery be achieved without losing tests in progress? How will the laboratory function when the catastrophe comes? How will we provide essential services if emergency power is acutely rationed because of fuel shortage, if the laboratory information system is off-line for several days, or if structural failure disrupts utilities? These traditional concerns should not be neglected as new technologies are adopted.
Scheduling algorithms are already in the laboratory, although not necessarily in a computer or expeditiously applied. At the highest level or layer of scheduling, samples are assayed stat or in a satellite laboratory or are sent to an outside laboratory. At a lower level, random-access instruments schedule tests to improve throughput, reduce sample-to-sample interference, and (or) reduce reagent costs. It seems unlikely that "expert systems" (a form of artificial intelligence) will provide a breakthrough because application of expert systems depends on a human experience base, and the full scheduling problem is too complex for humans. It seems improbable that "operations research" will provide a breakthrough because application of operations research methods is computer-intensive.
The use of heuristic algorithms created specifically for the clinical laboratory seems to be a fertile area. The evolution of these systems will probably progress in the areas of automated specimen processing and automated conveyance to analytical workstations.
How will scheduling affect the laboratory of the future? The fundamental drivers are economics, patient care, and quality. Productivity can be measured by the extent to which the best use is made of our education and skills. Automation that incorporates sophisticated scheduling reduces the high-value time spent on important but low-skill tasks. Improved patient care will include fewer blood draws. Automation and scheduling can divide specimens into aliquots, obviating the need for multiple tubes, and can also initiate reflexive testing, for reduced blood draws. Quality can be defined as meeting expectations. Scheduling can help to deliver quality by consistently delivering expected turnaround time (e.g., by prioritizing tests and possibly delaying low-priority tests for the same or other specimens).
Experience has shown that technologies for increasing productivity and reducing errors, e.g., use of bar-coded samples, have been slow to be adopted in clinical laboratories. Will the acceptance of preanalytical mechanization and sophisticated scheduling algorithms be any different? The labor cost savings in large (>600 bed) hospitals appears to justifr the substantial capital cost of these technologies. Perhaps 50% of the large hospitals will acquire mechanized sample processing with accompanying scheduling software by the year 2000; small (<300 bed) hospitals are unlikely to save enough labor to justify the capital cost. Further, as workstation consolidation continues, the potential labor to be saved will also decrease, thus reducing the potential cost savings that might be achieved. Perhaps <5% of small hospitals will implement mechanized sample processing and scheduling software by the year 2000. The situation for the medium-size hospital is unclear. The adoption of mechanized sample-processing systems will depend on the capital cost, which will in turn depend on the number of installations (the chicken vs the egg conundrum).
The general admonition applies here: Understand the issues before seeking the solution.
